Table 1.
Adverse events
| PC arm | AC arm (N = 354) | P value (PC-post vs. AC) |
||||||
|---|---|---|---|---|---|---|---|---|
| Preoperative (N = 382) | Postoperative (N = 364) | |||||||
| All | Grade 3/4 | All | Grade 3/4 | All | Grade 3/4 | All | Grade 3/4 | |
| Serious adverse events | 8(2.1%) | 3(0.8%) | 12(3.3%) | 6(1.6%) | 18(5.1%) | 11(3.1%) | 1.000 | 1.000 |
| Hematological | ||||||||
| Anemia | 251(65.7%) | 30(7.9%) | 191(52.5%) | 25(6.9%) | 201(56.8%) | 23(6.5%) | 0.246 | 0.842 |
| Leukopenia | 242(63.4%) | 16(4.2%) | 184(50.5%) | 19(5.2%) | 190(53.7%) | 14(4.0%) | 0.402 | 0.418 |
| Neutropenia | 209(54.7%) | 75(19.6%) | 173(47.5%) | 54(14.8%) | 162(45.8%) | 67(18.9%) | 0.636 | 0.143 |
| Thrombocytopenia | 292(76.4%) | 40(10.5%) | 250(68.7%) | 32(8.8%) | 243(68.6%) | 28(7.9%) | 0.991 | 0.670 |
| Non-hematological | ||||||||
| Anorexia | 267(69.9%) | 18(4.7%) | 219(60.2%) | 16(4.4%) | 231(65.3%) | 9(2.5%) | 0.159 | 0.176 |
| Diarrhea | 180(47.1%) | 12(3.1%) | 156(42.9%) | 9(2.5%) | 130(36.7%) | 11(3.1%) | 0.093 | 0.605 |
| Fatigue | 288(75.4%) | 20(5.2%) | 247(67.9%) | 12(3.3%) | 245(69.2%) | 14(4.0%) | 0.697 | 0.637 |
| Mucositis | 108(28.3%) | 2(0.5%) | 89(24.5%) | 1(0.3%) | 105(29.7%) | 3(0.8%) | 0.116 | 0.303 |
| Nausea | 261(68.3%) | 8(2.1%) | 201(55.2%) | 5(1.4%) | 191(54.0%) | 11(3.1%) | 0.734 | 0.116 |
| Neuropathy | 187(49.0%) | 14(3.7%) | 157(43.1%) | 15(4.1%) | 144(40.7%) | 9(2.5%) | 0.505 | 0.239 |
| Vomitting | 121(31.7%) | 6(1.6%) | 94(25.8%) | 8(2.2%) | 104(29.4%) | 8(2.3%) | 0.287 | 0.955 |
Chemotherapy population (patients who received at least one cycle of chemotherapy). Data are n (%). PC, perioperative chemotherapy; AC, adjuvant chemotherapy; PC-post, adverse events observed in postoperative chemotherapy in the PC group